Filing Overview
Registrant: NLS Pharmaceutics Ltd., not Newcelx Ltd. as stated in the request metadata. This Form 6-K covers March 2024 and was filed on March 20, 2024 under Commission file number 001-39957.
Material Business Development
On March 19, 2024, NLS Pharmaceutics entered into an exclusive license agreement with Aexon Labs Inc., a Delaware corporation. The agreement grants NLS an exclusive, royalty-bearing, sublicensable license relating to a next-generation non-sulfonamide dual orexin agonist platform for narcolepsy and other neurodegenerative disorders.
Financial Terms and Liquidity
- NLS must exercise its exclusive option no later than March 31, 2024 and pay Aexon an upfront fee of $170,000. If these conditions are not met, the agreement becomes null and void on April 1, 2024.
- Milestone payments range from $100,000 to $300,000 upon specified events.
- Royalty obligations range from 5% to 30% on a country-by-country basis, depending on regional earnings, patent status at commercialization, and whether patent validity is challenged.
- NLS must also pay Aexon a percentage of license fees, milestones, and royalties received from sublicensees.
- The filing does not provide revenue, profit, cash-flow, margin, debt, cash-balance, or liquidity figures.
Term, Outlook, and Risks
The license term generally extends until the later of the end of commercialization in the last applicable region or country and expiration of the last-to-expire valid patent claim covering the relevant products and uses, subject to earlier termination under the agreement.
- The agreement requires near-term funding of the $170,000 upfront payment and may require additional milestone payments.
- Future royalty and sublicense-sharing obligations could reduce economics from any successful commercialization or sublicensing.
- The license is conditional on NLS exercising its option by March 31, 2024; failure to do so would terminate the arrangement automatically on April 1, 2024.
- The filing provides no clinical, regulatory, commercialization, or financial guidance for the licensed platform.
Key Facts to Verify
- Whether NLS exercised the license option and paid the $170,000 upfront fee by March 31, 2024.
- The specific licensed compounds, patents, territories, development rights, termination provisions, and milestone triggers in the complete agreement.
- NLS’s available cash and financing sources for upfront, milestone, development, and commercialization obligations.
- Any subsequent filing confirming the agreement’s effectiveness, amendments, termination, or related clinical and regulatory progress.